prexasertib (ACR-368)

News alerts, weekly reports and conference planners

Company:

Acrivon Therap, Eli Lilly, Ewha Womans University, Pfizer, SOM Biotech

Drug class:

Chk2 inhibitor, Chk1 inhibitor

Related drugs:

No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	ACR-368 Sensitive: B - Late Trials ACR-368 Sensitive : B	ACR-368 Sensitive: B - Late Trials ACR-368 Sensitive : B
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	ACR-368 Sensitive: B - Late Trials ACR-368 Sensitive : B	ACR-368 Sensitive: B - Late Trials ACR-368 Sensitive : B
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	olaparib + ACR-368 Sensitive: C2 – Inclusion Criteria olaparib + ACR-368 Sensitive : C2	olaparib + ACR-368 Sensitive: C2 – Inclusion Criteria olaparib + ACR-368 Sensitive : C2
BRCA2 mutation	Ovarian Serous Adenocarcinoma	BRCA2 mutation	Ovarian Serous Adenocarcinoma	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	ACR-368 + LY3300054 Sensitive: C3 – Early Trials ACR-368 + LY3300054 Sensitive : C3	ACR-368 + LY3300054 Sensitive: C3 – Early Trials ACR-368 + LY3300054 Sensitive : C3
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	ACR-368 + LY3023414 Sensitive: C3 – Early Trials ACR-368 + LY3023414 Sensitive : C3	ACR-368 + LY3023414 Sensitive: C3 – Early Trials ACR-368 + LY3023414 Sensitive : C3
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3
BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3
BRCA1 3363delGAAA	Triple Negative Breast Cancer	BRCA1 3363delGAAA	Triple Negative Breast Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D
BRCA1 5396insC	Triple Negative Breast Cancer	BRCA1 5396insC	Triple Negative Breast Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D
BRCA2 5396insC	Triple Negative Breast Cancer	BRCA2 5396insC	Triple Negative Breast Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D
CACNA1D E953D	Triple Negative Breast Cancer	CACNA1D E953D	Triple Negative Breast Cancer	ACR-368 Resistant: D – Preclinical ACR-368 Resistant : D	ACR-368 Resistant: D – Preclinical ACR-368 Resistant : D
TP53 R273H	Triple Negative Breast Cancer	TP53 R273H	Triple Negative Breast Cancer	ACR-368 Resistant: D – Preclinical ACR-368 Resistant : D	ACR-368 Resistant: D – Preclinical ACR-368 Resistant : D
PTEN V85	Triple Negative Breast Cancer	PTEN V85	Triple Negative Breast Cancer	ACR-368 Resistant: D – Preclinical ACR-368 Resistant : D	ACR-368 Resistant: D – Preclinical ACR-368 Resistant : D
BRCA2 deletion	Prostate Cancer	BRCA2 deletion	Prostate Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D
BRCA2 mutation	Ovarian Serous Adenocarcinoma	BRCA2 mutation	Ovarian Serous Adenocarcinoma	ACR-368 + LY3023414 Sensitive: D – Preclinical ACR-368 + LY3023414 Sensitive : D	ACR-368 + LY3023414 Sensitive: D – Preclinical ACR-368 + LY3023414 Sensitive : D
BCL2L1 overexpression	Pancreatic Cancer	BCL2L1 overexpression	Pancreatic Cancer	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D
CHEK1 overexpression	Pancreatic Cancer	CHEK1 overexpression	Pancreatic Cancer	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D
CHEK1 overexpression + MYC overexpression	Small Cell Lung Cancer	CHEK1 overexpression + MYC overexpression	Small Cell Lung Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D
MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D

prexasertib (ACR-368)

Associations
(25)

Associations
(25)

prexasertib (ACR-368)

Associations(25)

Associations(25)

Associations
(25)

Associations
(25)